Do you want to read an article? Please log in or register.
Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial
Interstitial Lung Disease
RECOMMENDED
Related content
RECOMMENDED
Interstitial Lung DiseasePulmonary Fibrosis
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med.
Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M, INBUILD trial investigators.
doi: 10.1016/S2213-2600(20)30036-9.
RECOMMENDED
Interstitial Lung DiseasePulmonary Fibrosis
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
N Engl J Med.
Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK, INBUILD Trial Investigators.
doi: 10.1056/NEJMoa1908681.
RECOMMENDED
Interstitial Lung Disease
Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Respir Med
Inoue Y, Suda T, Kitamura H, Okamoto M, Azuma A, Inase N, Kuwana M, Makino S, Nishioka Y, Ogura T, Takizawa A, Ugai H, Stowasser S, Schlenker-Herceg R, Takeuchi T
doi: 10.1016/j.rmed.2021.106574
RECOMMENDED
Interstitial Lung Disease
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Ann Rheum Dis.
Seibold JR, Maher TM, Highland KB, Assassi S, Azuma A, Hummers LK, Costabel U, von Wangenheim U, Kohlbrenner V, Gahlemann M, Alves M, Distler O, SENSCIS trial investigators
doi: 10.1136/annrheumdis-2020-217331.
RECOMMENDED
Interstitial Lung DiseasePulmonary FibrosisPneumonia
Effects of nintedanib by inclusion criteria for progression of interstitial lung disease
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Eur Respir J
Maher TM, Brown KK, Kreuter M, Devaraj A, Walsh SLF, Lancaster LH, Belloli EA, Padilla M, Behr J, Goeldner RG, Tetzlaff K, Schlenker-Herceg R, Flaherty KR, INBUILD trial investigators.
doi: 10.1183/13993003.04587-2020
RECOMMENDED
Interstitial Lung DiseasePulmonary Fibrosis
The natural history of progressive fibrosing interstitial lung diseases
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
★ 2
Recommended by
Dr Martin Frey, Faculty Member
doi: 10.1183/13993003.00085-2020.
RECOMMENDED
Interstitial Lung DiseasePulmonary Fibrosis
Potential of Nintedanib in Treatment of Progressive Fibrosing Interstitial Lung Diseases
Eur Respir J.
Wollin L, Distler JHW, Redente EF, Riches DWH, Stowasser S, Schlenker-Herceg R, Maher TM, Kolb M
doi: 10.1183/13993003.00161-2019.
RECOMMENDED
Interstitial Lung Disease
Closing the Evidence Gap in Interstitial Lung Disease: The Promise of Real World Data
Am J Respir Crit Care Med.
Farrand E, Anstrom KJ, Bernard G, Butte AJ, Iribarren C, Ley B, Martinez F, Collard HR
doi: 10.1164/rccm.
RECOMMENDED
Interstitial Lung Disease
The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Eur Respir J
Birring SS, Bushnell DM, Baldwin M, Mueller H, Male N, Rohr KB, Inoue Y
doi: 10.1183/13993003.01790-2021